Piper Sandler Remains a Buy on Context Therapeutics (CNTX)
Piper Sandler analyst Biren Amin reiterated a Buy rating on Context Therapeutics (CNTX – Research Report) on June 26 and set a price target of $4.00. The company’s shares closed last Friday at $0.66. Don’t Miss TipRanks’ Half Year Sale According to …